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orticosteroid Therapy
fter Catheter Ablation
f Atrial Fibrillation for an
uthentic “Blanking Period”*
ernard Belhassen, MD
el Aviv, Israel
atheter ablation of paroxysmal and persistent atrial fibril-
ation (AF) is being performed with increasing frequency
orldwide. The most frequent untoward event associated with
he procedure is recurrent atrial tachyarrhythmias, which have
een observed in as many as 65% of patients within the first 3
onths after ablation (1–6). These arrhythmias are often
ransient and are generally considered to be poor predictors of
he long-term outcome of the procedure (1,2,4–6). Therefore,
ost investigators have defined a “blanking period” of 3
onths post-procedure during which these arrhythmias are
ot taken into account in terms of success or failure (6). For the
atient, however, this period may represent a tumultuous phase
uring which there may be a need for drug adjustments,
ospitalization, or electrical cardioversion.
See page 1463
Few studies have addressed the management of atrial
achyarrhythmias that occur during the early post-ablation
eriod. Roux et al. (7) showed that empirical use of
ntiarrhythmic drugs for the 6 weeks after the procedure
ignificantly reduced the occurrence of significant atrial
rrhythmias, including those requiring cardioversion or
ospitalization, in patients with paroxysmal AF who un-
ergo pulmonary vein isolation. Lellouche et al. (3) showed
hat an early second ablation procedure (i.e., within the first
onth after the index ablation) reduced the incidence of
rrhythmia recurrences. Both the antiarrhythmic and abla-
ion modes of treatment used in those studies, however,
ere not based on the mechanism involved in the atrial
achyarrhythmias that occur shortly after AF ablation.
Editorials published in the Journal of the American College of Cardiology reflect the
iew of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiac Electrophysiology Laboratory, Department of Cardiology, Tel
viv Sourasky Medical Center, Tel Aviv, Israel; and the Sackler School of Medicine,a
el Aviv University, Tel Aviv, Israel. Dr. Belhassen has reported that he has no
elationships to disclose.he Role of Inflammation in AF
number of studies have indicated that inflammation
ight play a significant role in the initiation, maintenance,
nd perpetuation of AF and that C-reactive protein (CRP)
s related to the mechanism responsible for the processes
eading to AF (8–12). Local and systemic inflammation
reated by the myocardial damage resulting from radiofre-
uency burns seems to play a prominent role in patients
ndergoing ablation. Moreover, inflammatory processes
ay participate in the heterogeneity of the action potential
uration of the atrial and/or pulmonary vein myocardium by
hemical mediators and may ultimately result in the creation
f arrhythmogenic substrate (13). A similar mechanism has
een suggested to explain the atrial arrhythmias occurring
arly after cardiac surgery, acute myocardial infarction, or
uccessful electrical cardioversion (11,14).
orticosteroid Therapy in AF Prophylaxis
he widest experience with the effect of corticosteroid
herapy on AF prophylaxis has been accumulating during
he past 30 years in adult cardiac surgery patients. In a
eta-analysis of 50 randomized controlled trials, Ho and
an (14) showed that intravenous corticosteroid therapy
efore and/or after cardiopulmonary bypass was associated
ith a significant reduction in the risk of AF. In 1 study,
lucocorticoid therapy significantly reduced the risk of
ecurrent and permanent AF in patients with AF that was
ot secondary to a precipitating condition (10). In contrast,
n 2 large population-based, case-control studies, an in-
reased risk of AF was found during current use (15) or a
igh-dose regimen (16) of oral corticosteroid therapy.
orticosteroid Therapy After AF Ablation
n this issue of the Journal, Koyama et al. (17) reported the
rst study that evaluated the effects of corticosteroids on the
ate of AF recurrence in patients who underwent pulmonary
ein ablation for symptomatic paroxysmal AF. This pro-
pective, double-blind, randomized study involved 125 pa-
ients (60 in the corticosteroid-treated group and 65 in the
lacebo group). Patients in the corticosteroid group were
iven intravenous hydrocortisone (2 mg/kg) immediately
fter the procedure followed by oral prednisolone (0.5
g/kg/day) for 3 days after the procedure. All of the
atients underwent clinical, electrocardiographic, and bio-
ogical monitoring that included measurements of body
emperature (BT) and high-sensitivity CRP levels during 3
onsecutive days after the ablation procedure. After 1 week
f hospitalization, all of the patients were regularly followed
p with 24-h Holter electrocardiographic and portable
lectrocardiographic monitoring during a 14-month period.
he arrhythmias observed during the first month after
blation were classified as immediate AF (during the first 3
ays), early AF (between days 3 and 30), and no AF (no
rrhythmia recurrence during the first 30 days).
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Corticosteroid Therapy After Catheter Ablation October 26, 2010:1473–5The main results of the study were 3-fold. 1) Corticoste-
oid therapy led to a significant reduction in AF recurrence
ate during the first month after ablation (27% and 49% in
he treated and placebo groups, respectively). This was
ainly achieved due to a marked reduction in immediate
F recurrence rate (7% and 31%, respectively), whereas the
ate of early AF recurrence remained similar in both groups
20% and 18%, respectively). 2) Eighty-five percent of the
orticosteroid group had no AF recurrences without any
ntiarrhythmic drugs 14 months after ablation compared
ith 71% in the placebo group (p  0.05). 3) The maximal
T and CRP levels during the initial 3 days after ablation
nd the increase in BT and CRP levels between baseline and
he 3-day time point were significantly lower in the corti-
osteroid group than in the placebo group. The authors also
oted that there were no side effects that could be attributed
o the treatment. In a previous study that the same inves-
igators had conducted with a different and larger patient
ohort (n  186) (13), immediate AF recurrence was more
losely associated with an acute inflammatory process (as
ttested by changes in BT and CRP levels) than early AF
ecurrence. In addition, after a 6-month follow-up, the
F-free rate was significantly greater in the immediate AF
ecurrence group (76%) than in the early AF recurrence
roup (30%).
The present study is well designed and provides the first
bjective evidence that the immediate atrial tachyarrhyth-
ias occurring during the first 3 days after AF ablation are
ue to an inflammatory response that can be significantly
ecreased by a short course of corticosteroid therapy. The
arly arrhythmias occurring between days 3 and 30 were not,
owever, associated with an inflammatory response, thereby
upporting the results of studies suggesting that such ar-
hythmias may be due to pulmonary vein–left atrium con-
uction recovery (18). Irrespective of the specific mecha-
ism of action of corticosteroid therapy on the various
rrhythmic periods after ablation, it is gratifying that this
herapy resulted in a 50% reduction rate of AF events during
he first month after AF ablation. Although the study by
oyama et al. (17) did not provide data on the consequences
f AF recurrences for the patients in terms of need for
ntiarrhythmic medication adjustments, hospitalization, or
lectrical cardioversion, the decrease in the AF burden is
ery likely to improve the quality of life for some patients
nd possibly increase the cost-effectiveness of the procedure
s well. As the authors stated, their finding of a small but
ignificant lower recurrence rate of AF at the 14-month
ollow-up post-ablation is difficult to explain by the short
ourse of corticosteroid therapy and warrants further
onfirmation.
tudy Limitations
he study of Koyama et al. (17) has several limitations,
ome of which were acknowledged and addressed by the
uthors. 1) The population size of the study is relativelymall. 2) The authors used CRP and BT as markers of
nflammation of the ablated myocardium, but these markers
ack specificity. 3) There is no information about the
roportion of patients with diabetes mellitus, one of the
ost prominent conditions associated with AF (19). Ac-
ording to a recent report (20), this population should not
e excluded from undergoing AF ablation. 4) The informa-
ion on safety and tolerance of corticosteroid therapy is
nsufficient. No data were provided on blood glucose con-
entrations in the corticosteroid-treated group despite the
act that blood glucose levels are expected to increase in both
ondiabetic and type 2 diabetes patients (14,21). 5) Finally,
he authors did not discuss the possible deleterious effect
f corticosteroid therapy on slowing the healing of the
blated tissues, an effect that could favor late cardiac
erforations (22).
linical Implications
he significant reduction in the rate of post-ablation atrial
achyarrhythmias during the blanking period by means of a
hort course of corticosteroid therapy is interesting and may
e clinically important. This finding should stimulate fur-
her studies on the long-term safety and the clinical and
ost-effective benefits of this therapy. The question of
hether the results of the present study should prompt us to
nclude corticosteroid therapy in our routine practice or
hether we should wait for confirming studies is difficult to
nswer. In any event, the authors should be congratulated
or making a contribution that will undoubtedly encourage
urther work on these critical issues.
eprint requests and correspondence: Dr. Bernard Belhassen,
epartment of Cardiology, Tel Aviv Sourasky Medical Center,
eizman Street 6, Tel Aviv 64239, Israel. E-mail: bblhass@
asmc.health.gov.il.
EFERENCES
1. Oral H, Knight BP, Ozyaydin M, et al. Clinical significance of early
recurrences of atrial fibrillation after pulmonary vein isolation. J Am
Coll Cardiol 2002;40:100–4.
2. Lee SH, Tai CT, Hsieh MH, et al. Predictors of early and late
recurrence of atrial fibrillation after catheter ablation of paroxysmal
atrial fibrillation. J Interv Card Electrophysiol 2004;10:221–6.
3. Lellouche N, Jais P, Nault I, et al. Early recurrences after atrial
fibrillation ablation: prognostic value and effect on early reablation.
J Cardiovasc Electrophysiol 2008;19:599–605.
4. Themistoclakis S, Schweikert RA, Saliba WI, et al. Clinical predictors
and relationship between early and late atrial tachyarrhythmias after
pulmonary vein antrum isolation. Heart Rhythm 2008;5:679–85.
5. Richter B, Gwechenberger M, Socas A, Marx M, Gossinger HD.
Frequency of recurrence of atrial fibrillation within 48 hours after
ablation and its impact on long-term outcome. Am J Cardiol 2008;
101:843–7.
6. Joshi S, Choi AD, Kamath GS, et al. Prevalence, predictors, and
prognosis of atrial fibrillation early after pulmonary vein isolation:
findings from 3 months of continuous automatic ECG loop record-
ings. J Cardiovasc Electrophysiol 2009;20:1089–94.7. Roux JF, Zado E, Callans DJ, et al. Antiarrhythmics after ablation of
atrial fibrillation (5A Study). Circulation 2009;22;120:1036–40.
11
1
1
1
1
1
1
1
1
2
2
2
K
1475JACC Vol. 56, No. 18, 2010 Belhassen
October 26, 2010:1473–5 Corticosteroid Therapy After Catheter Ablation8. Chung M, Martin D, Sprecher D, et al. C-reactive protein elevation
in patients with atrial arrhythmias. Inflammatory mechanism and
persistence of atrial fibrillation. Circulation 2001;104:2886–91.
9. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a
risk factor for atrial fibrillation. Circulation 2003;108:3006–10.
0. Dernellis J, Panaretou M. Relationship between C-reactive protein
concentrations during glucocorticoid therapy and recurrent atrial
fibrillation. Eur Heart J 2004;25:1100–7.
1. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in
initiation and perpetuation of atrial fibrillation. J Am Coll Cardiol
2007;50:2021–8.
2. Marcus GM, Smith LM, Ordovas K, et al. Intracardiac and extracar-
diac markers of inflammation during atrial fibrillation. Heart Rhythm
2010;7:149–54.
3. Koyama T, Sekiguchi Y, Tada H, et al. Comparison of characteristics
and significance of immediate versus early versus no recurrence of atrial
fibrillation after catheter ablation. Am J Cardiol 2009;103:1249–54.
4. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in
adult cardiac surgery: a dose-response meta-analysis. Circulation
2009;119:1853–66.
5. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Cha-
purlat RD, Sorensen HT. Glucocorticoid use and risk of atrial
fibrillation or flutter. A population-based, case-control study. Arch
Intern Med 2009;169:1677–83.
6. Van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids
and the risk of atrial fibrillation. Arch Intern Med 2006;165:1016–20. i7. Koyama T, Tada H, Sekiguchi Y, et al. Prevention of atrial fibrillation
recurrence with corticosteroids after radiofrequency catheter ablation:
a randomized controlled trial. J Am Coll Cardiol 2010;56:1463–72.
8. Ouyang F, Antz M, Ernst S, et al. Recovered pulmonary vein
conduction as a dominant factor for recurrent atrial tachyarrhythmias
after complete circular isolation of the pulmonary veins: lessons from
double Lasso technique. Circulation 2005;111:127–35.
9. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospi-
talization for atrial fibrillation in the United States, 1985 through
1999: implications for primary prevention. Circulation 2003;108:
711–6.
0. Forleo GB, Mantica M, De Luca L, et al. Catheter ablation of atrial
fibrillation in patients with diabetes mellitus type 2: results from a
randomized study comparing pulmonary vein isolation versus antiar-
rhythmic drug therapy. J Cardiovasc Electrophysiol 2009;20:22–8.
1. Hans P, Vanthuyne A, Dewandre PY, Brichant JF, Bonhomme V.
Blood glucose concentration profile after 10mg dexamethasone in
non-diabetic and type 2 diabetic patients undergoing abdominal
surgery. Br J Anaesth 2006;97:164–70.
2. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the
cardiovascular system. Can J Cardiol 2000;16:505–11.
ey Words: ablation y atrial fibrillation y corticosteroid y
nflammatory response y recurrence.
